Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers

References

• NCEP Expert PanelThird Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation2002106253143342112485966
   PubMed Web of Science ®Google Scholar
• BrunzellJDDavidsonMFurbergCDLipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology FoundationDiabetes Care200831481182218375431
   PubMed Web of Science ®Google Scholar
• CatapanoALReinerZDe BackerGESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Atherosclerosis2011217SS1S4421723445
   PubMedGoogle Scholar
• ContoisJHMcConnellJPSethiAAApolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best PracticesClin Chem200955340741919168552
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet2004364943893795215364185
   PubMed Web of Science ®Google Scholar
• St-PierreACCantinBDagenaisGRLow-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular StudyArterioscler Thromb Vasc Biol200525355355915618542
   PubMed Web of Science ®Google Scholar
• HolmeIAastveitAHHammarNJungnerIWalldiusGInflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS)Atherosclerosis2010213129930520843515
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMSchoenhagenPStatin therapy, LDL cholesterol, C-reactive protein, and coronary artery diseaseN Engl J Med20053521293815635110
   PubMed Web of Science ®Google Scholar
• DruckerDJShermanSIGorelickFSBergenstalRMSherwinRSBuseJBIncretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefitsDiabetes Care201033242843320103558
   PubMed Web of Science ®Google Scholar
• BhushanRElkind-HirschKEBhushanMButlerWJDuncanKMarrioneauxOImproved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice settingDiabetes Technol Ther200911635335919459763
   PubMed Web of Science ®Google Scholar
• BunckMCCornérAEliassonBOne-year treatment with exenatide vs insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stressAtherosclerosis2010212122322920494360
   PubMed Web of Science ®Google Scholar
• KoskaJSchwartzEAMullinMPSchwenkeDCReavenPDImprovement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetesDiabetes Care20103351028103020200309
   PubMed Web of Science ®Google Scholar
• OkersonTYanPStonehouseABrodowsREffects of exenatide on systolic blood pressure in subjects with type 2 diabetesAm J Hypertens201023333433920019672
   PubMed Web of Science ®Google Scholar
• NauckMADuranSKimDA comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia200750225926717160407
   PubMed Web of Science ®Google Scholar
• KapitzaCNauckMTrautmannMLong-term treatment with exenatide was associated with improved post-prandial glycaemic control and a shift from small to large HDL and LDL particlesDiabet Med200623Suppl 4S4
   Google Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet200837296451240125018782641
   PubMed Web of Science ®Google Scholar
• KulkarniKRCholesterol profile measurement by vertical auto profile methodClin Lab Med2006269478780217110240
   PubMed Web of Science ®Google Scholar
• KulkarniKRGarberDWMarcovinaSMSegrestJPQuantification of cholesterol in all lipoprotein classes by the VAP-II methodJ Lipid Res19943511591688138718
   PubMed Web of Science ®Google Scholar
• Atherotech Diagnostics LabThe VAP cholesterol test2012 Available from: http://www.atherotech.comAccessed October 14, 2011
   Google Scholar
• [No authors listed]Standards of medical care in diabetes – 2012Diabetes Care201235Suppl 1S11S6322187469
   PubMed Web of Science ®Google Scholar
• SuperkoHRAdvanced lipoprotein testing and subfractionation are clinically usefulCirculation2009119172383239519414656
   PubMed Web of Science ®Google Scholar
• SnidermanADWilliamsKContoisJHA meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular riskCirc Cardiovasc Qual Outcomes20114333734521487090
   PubMed Web of Science ®Google Scholar
• FranceschiniGBondioliAGranataDReduced HDL2 levels in myocardial infarction patients without risk factors for atherosclerosisAtherosclerosis19876832132193426654
   PubMed Web of Science ®Google Scholar
• MillerMStoneNJBallantyneCTriglycerides and cardiovascular disease: a scientific statement from the American Heart AssociationCirculation2011123202292233321502576
   PubMed Web of Science ®Google Scholar
• BlondeLKleinEJHanJInterim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetesDiabetes Obes Metab20068443644716776751
   PubMed Web of Science ®Google Scholar
• KlonoffDCBuseJBNielsenLLExenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurr Med Res Opin200824127528618053320
   PubMed Web of Science ®Google Scholar
• SchwartzEAKoskaJMullinMPSyoufiISchwenkeDCReavenPDExenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitusAtherosclerosis2010212121722220557887
   PubMed Web of Science ®Google Scholar
• BergenstalRMWyshamCMacconellLEfficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialLancet2010376973943143920580422
   PubMed Web of Science ®Google Scholar
• WyshamCBergenstalRMalloyJDURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatideDiabet Med201128670571421434995
   PubMed Web of Science ®Google Scholar
• XiaoCBandsmaRHDashSSzetoLLewisGFExenatide, a glucagon- like peptide receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humansArterioscler Thromb Vasc Biol20123261513151922492091
   PubMed Web of Science ®Google Scholar
• BaysHMandarinoLDeFronzoRARole of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approachJ Clin Endocrinol Metab200489246347814764748
   PubMed Web of Science ®Google Scholar
• SoinioMMarniemiJLaaksoMLehtoSRonnemaaTHigh-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up studyDiabetes Care200629232933316443882
   PubMed Web of Science ®Google Scholar
• WuJDXuXHZhuJEffect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitusDiabetes Technol Ther201113214314821284481
   PubMed Web of Science ®Google Scholar